Boehringer Ingelheim said survodutide, its once-weekly glucagon and GLP-1 dual agonist licensed from Zealand Pharma, met the primary endpoint of the Phase 3 SYNCHRONIZE-CVOT cardiovascular safety trial, presented at the American Heart Association Scientific Sessions on November 9 and published simultaneously in The Lancet. The event-driven trial enrolled 5,530 adults with obesity or overweight and established cardiovascular disease, chronic kidney disease, or at least two weight-related complications or risk factors.
Survodutide did not increase the risk of the five-point major adverse cardiovascular events composite, covering cardiovascular death, non-fatal heart attack, non-fatal stroke, coronary revascularisation and heart failure events, against placebo. The hazard ratio was 0.89, with a 95 percent confidence interval of 0.67 to 1.18, and the trial met its noninferiority test. That distinction matters: because the interval crosses 1.0, the trial establishes cardiovascular safety, not cardiovascular benefit. On secondary endpoints, the company reported reductions in systolic blood pressure and waist circumference at 72 weeks against placebo.
Boehringer said it is the first global cardiovascular safety trial of a glucagon and GLP-1 dual agonist, and that, based on the full SYNCHRONIZE programme, it is preparing regulatory submissions for survodutide in obesity. The drug is not approved for any use. It is also in Phase 3 trials in metabolic dysfunction-associated steatohepatitis, LIVERAGE and LIVERAGE-Cirrhosis.
The commercial question is separate from the safety answer, and Endpoints framed the filing plan around it: entering a market defined by Lilly’s and Novo’s products means the safety clearance is a ticket to compete, not a share gain. Analyst reaction reported by BioSpace was similarly qualified, with William Blair expecting clinical use to concentrate in patients with elevated liver-related risk factors, where the glucagon component and the liver programme give survodutide its clearest differentiation.